• Early Virologic Response [ Time Frame: After 12 weeks of Treatment ] [ Designated as safety issue: No ]
  
• End of Treatment Response [ Time Frame: 48 Weeks ] [ Designated as safety issue: No ]
  
• Sustained Virologic Response [ Time Frame: 24 weeks after Treatment ] [ Designated as safety issue: No ]
  
• Rapid Virologic Response [ Time Frame: One month after Treatment ] [ Designated as safety issue: No ]
  

• Tolerability of drugs for whole therapy period [ Time Frame: During Treatment ] [ Designated as safety issue: Yes ]
  
• Biochemical response (ALT) [ Time Frame: End of Treatment AND 24 weeks after Treatment ] [ Designated as safety issue: No ]
  
• Laboratory Parameters [ Time Frame: During Treatment AND End of treatment ] [ Designated as safety issue: No ]
  

Patients with Thalassemia receive chronic blood transfusions and have an increased prevalence of chronic Hepatitis C virus (HCV) infection, particularly if transfused before HCV serological testing became available. The investigators enrolled 300 patients into the study. The patients received PEGASYS (Peginterferon alpha-2a(40 KD)) 180 microgram per week plus COPEGUS (Ribavirin) 1000 milligram for weight less than or equal 75 kg and 1200 milligram for more than 75 kg for 48 weeks. Follow up period is 6 months after treatment. The patients are visited every 4 weeks with biochemistry lab tests. The patients are checked with quantitative HCV RNA (Ribonucleic Acid) on the third months after initiation of the treatment to assess early virologic response and at the end of the study for complete response rate and on the six month after treatment completion for sustained response rate. The patients with undetectable HCV RNA are considered as responders.